Reviva Pharmaceuticals Holdings, Inc. - Common Stock (RVPH)
1.8900
+0.0500 (2.72%)
Reviva Pharmaceuticals Holdings Inc. is a biopharmaceutical company focused on developing innovative therapeutic solutions for conditions with significant unmet medical needs
The company primarily concentrates on advancing its proprietary drug candidates through clinical trials to address psychiatric, neurological, and inflammatory disorders. Reviva utilizes its expertise in pharmacology to create novel treatment options that aim to improve the lives of patients by targeting specific mechanisms of disease while minimizing side effects associated with traditional therapies. Through its research and development efforts, Reviva seeks to make meaningful contributions to the field of medicine and enhance patient outcomes.
Reviva Pharmaceuticals Holdings Inc (NASDAQRVPH) shares are surging after the company released topline results of its pivotal Phase 3 RECOVER trial evaluating brilaroxazine, a serotonin-dopamine signaling modulator in
Reviva Pharmaceuticals Holdings Inc (NASDAQRVPH) announced the topline results of its pivotal Phase 3 RECOVER trial evaluating brilaroxazine, a serotonin-dopamine signaling modulator in
